In a strategic move that underscores confidence in Bio-Works Technologies, the company's two largest shareholders, Staffan Persson and Erik Åfors, have announced their intention to exercise all their outstanding Warrants of series TO 2 during the upcoming exercise period. This decision, involving both their personal holdings and those through Swedia Invest AB and Calyptra AB, represents a significant commitment to the company's future.

The exercise of these warrants, which amounts to a total of 13,666,044 TO 2 Warrants, is scheduled for the period from October 1 to October 14, 2025. Upon completion, Bio-Works will receive SEK 13,666,044 before issue costs, providing a substantial boost to its capital reserves.

Bio-Works Technologies, headquartered in Uppsala, Sweden, plays a crucial role in the biotech industry by enabling companies to purify biomolecules efficiently. The company has established itself as a trusted partner, supporting customers from laboratory research to commercial production with robust bioprocessing solutions. Its global reach, facilitated by a combination of direct sales and distributors across Europe, North America, and Asia, positions it well for continued growth.

This capital injection is expected to further bolster Bio-Works' capacity to innovate and expand its market presence. The decision by Persson and Åfors signals strong belief in the company's strategic direction and potential for future success.

For investors, this development presents a compelling case for confidence in Bio-Works Technologies. The exercise of warrants by major shareholders often indicates a positive outlook on the company's prospects. Given the current trajectory and the infusion of new capital, the recommendation for investors is to hold their positions. This allows them to benefit from potential future gains as Bio-Works continues to execute its growth strategy.